Ken Griffin Vir Biotechnology, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 20,600 shares of VIR stock, worth $159,444. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,600

Previous 28,100 26.69%

Holding current value

$159,444

Previous $284,000 35.56%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$7.63 - $12.66 $20.3 Million - $33.6 Million	-2,657,845 Reduced 77.99%	749,987 $6.67 Million
Q1 2024 May 15, 2024	BUY	$8.6 - $11.9 $3.18 Million - $4.4 Million	369,884 Added 12.18%	3,407,832 $34.5 Million
Q4 2023 Feb 14, 2024	BUY	$7.76 - $10.29 $22.9 Million - $30.4 Million	2,954,409 Added 3536.56%	3,037,948 $30.6 Million
Q3 2023 Nov 14, 2023	BUY	$9.14 - $24.62 $178,851 - $481,764	19,568 Added 30.59%	83,539 $782,000
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $6.21 Million - $7.31 Million	-267,822 Reduced 80.72%	63,971 $1.57 Million
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $6.76 Million - $9.37 Million	303,587 Added 1076.32%	331,793 $7.72 Million
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $1.87 Million - $2.65 Million	-93,754 Reduced 76.87%	28,206 $713,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $2.23 Million - $3.79 Million	121,960 New	121,960 $2.35 Million
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $14 Million - $24.4 Million	451,777 Added 324.79%	590,876 $24.7 Million
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $3.78 Million - $5.91 Million	108,342 Added 352.25%	139,099 $6.05 Million
Q2 2021 Aug 16, 2021	BUY	$38.75 - $51.0 $682,465 - $898,212	17,612 Added 133.98%	30,757 $1.45 Million
Q1 2021 May 17, 2021	SELL	$26.34 - $83.07 $298,721 - $942,096	-11,341 Reduced 46.32%	13,145 $674,000
Q4 2020 Feb 16, 2021	SELL	$25.51 - $43.38 $1.18 Million - $2 Million	-46,153 Reduced 65.34%	24,486 $656,000
Q3 2020 Nov 16, 2020	SELL	$28.28 - $53.6 $2.66 Million - $5.03 Million	-93,890 Reduced 57.07%	70,639 $2.43 Million
Q2 2020 Aug 14, 2020	BUY	$27.89 - $47.86 $4.59 Million - $7.87 Million	164,529 New	164,529 $6.74 Million
Q1 2020 May 15, 2020	SELL	$12.04 - $60.2 $232,335 - $1.16 Million	-19,297 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.83 - $15.85 $228,283 - $305,857	19,297 New	19,297 $243,000

Others Institutions Holding VIR

# of Institutions

232

Shares Held

87.6M

Call Options Held

231K

Put Options Held

132K

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.03B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account